Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells.

Urbanowicz RA, Wang R, Schiel JE, Keck ZY, Kerzic MC, Lau P, Rangarajan S, Garagusi KJ, Tan L, Guest JD, Ball JK, Pierce BG, Mariuzza RA, Foung SKH, Fuerst TR.

J Virol. 2019 Mar 21;93(7). pii: e01403-18. doi: 10.1128/JVI.01403-18. Print 2019 Apr 1.

2.

In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.

Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel MB, Pessaux P, Keck ZY, Schuster C, Fuerst TR, Foung SKH, Baumert TF.

Antiviral Res. 2019 Feb;162:136-141. doi: 10.1016/j.antiviral.2018.12.018. Epub 2018 Dec 30.

PMID:
30599173
3.

Structural basis for broad neutralization of ebolaviruses by an antibody targeting the glycoprotein fusion loop.

Janus BM, van Dyk N, Zhao X, Howell KA, Soto C, Aman MJ, Li Y, Fuerst TR, Ofek G.

Nat Commun. 2018 Sep 26;9(1):3934. doi: 10.1038/s41467-018-06113-4.

4.

Hydrolytically Degradable PEGylated Polyelectrolyte Nanocomplexes for Protein Delivery.

Andrianov AK, Marin A, Martinez AP, Weidman JL, Fuerst TR.

Biomacromolecules. 2018 Aug 13;19(8):3467-3478. doi: 10.1021/acs.biomac.8b00785. Epub 2018 Jul 13.

PMID:
29953203
5.

Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus.

Fuerst TR, Pierce BG, Keck ZY, Foung SKH.

Front Microbiol. 2018 Jan 15;8:2692. doi: 10.3389/fmicb.2017.02692. eCollection 2017. Review.

6.

Biodegradable "Smart" Polyphosphazenes with Intrinsic Multifunctionality as Intracellular Protein Delivery Vehicles.

Martinez AP, Qamar B, Fuerst TR, Muro S, Andrianov AK.

Biomacromolecules. 2017 Jun 12;18(6):2000-2011. doi: 10.1021/acs.biomac.7b00537. Epub 2017 May 30.

PMID:
28525259
7.

Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.

Pierce BG, Keck ZY, Lau P, Fauvelle C, Gowthaman R, Baumert TF, Fuerst TR, Mariuzza RA, Foung SKH.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E6946-E6954. doi: 10.1073/pnas.1614942113. Epub 2016 Oct 26.

8.

Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice.

Keck ZY, Wang Y, Lau P, Lund G, Rangarajan S, Fauvelle C, Liao GC, Holtsberg FW, Warfield KL, Aman MJ, Pierce BG, Fuerst TR, Bailey JR, Baumert TF, Mariuzza RA, Kneteman NM, Foung SK.

Hepatology. 2016 Dec;64(6):1922-1933. doi: 10.1002/hep.28850. Epub 2016 Oct 28.

9.

Molecular-Level Interactions of Polyphosphazene Immunoadjuvants and Their Potential Role in Antigen Presentation and Cell Stimulation.

Andrianov AK, Marin A, Fuerst TR.

Biomacromolecules. 2016 Nov 14;17(11):3732-3742. Epub 2016 Oct 24.

PMID:
27748602
10.

Self-assembly of polyphosphazene immunoadjuvant with poly(ethylene oxide) enables advanced nanoscale delivery modalities and regulated pH-dependent cellular membrane activity.

Andrianov AK, Marin A, Fuerst TR.

Heliyon. 2016 Apr 22;2(4):e00102. doi: 10.1016/j.heliyon.2016.e00102. eCollection 2016 Apr.

11.

Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody.

Li Y, Pierce BG, Wang Q, Keck ZY, Fuerst TR, Foung SK, Mariuzza RA.

J Biol Chem. 2015 Apr 17;290(16):10117-25. doi: 10.1074/jbc.M115.643528. Epub 2015 Mar 3.

12.

Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactions.

Watkinson A, Soliakov A, Ganesan A, Hirst K, Lebutt C, Fleetwood K, Fusco PC, Fuerst TR, Lakey JH.

Clin Vaccine Immunol. 2013 Nov;20(11):1659-68. doi: 10.1128/CVI.00320-13. Epub 2013 Aug 28.

13.

Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.

Leffel EK, Bourdage JS, Williamson ED, Duchars M, Fuerst TR, Fusco PC.

Clin Vaccine Immunol. 2012 Aug;19(8):1158-64. doi: 10.1128/CVI.00240-12. Epub 2012 Jun 13.

14.

In vitro infection and replication of hepatitis E virus in primary cynomolgus macaque hepatocytes.

Tam AW, White R, Yarbough PO, Murphy BJ, McAtee CP, Lanford RE, Fuerst TR.

Virology. 1997 Nov 10;238(1):94-102.

15.

Purification and characterization of a recombinant hepatitis E protein vaccine candidate by liquid chromatography-mass spectrometry.

McAtee CP, Zhang Y, Yarbough PO, Fuerst TR, Stone KL, Samander S, Williams KR.

J Chromatogr B Biomed Appl. 1996 Oct 11;685(1):91-104.

PMID:
8930757
16.

Purification of a soluble hepatitis E open reading frame 2-derived protein with unique antigenic properties.

McAtee CP, Zhang Y, Yarbough PO, Bird T, Fuerst TR.

Protein Expr Purif. 1996 Sep;8(2):262-70.

PMID:
8812876
17.

Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.

Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, Goldstein S, Piatak M Jr, Elkins WR, Alvord WG, Montefiori DC, Moss B, Lifson JD.

J Virol. 1996 Jun;70(6):3741-52.

18.

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.

Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, Elkins WR, Fuerst TR, Lifson JD, Piatak M, Restifo NP, Overwijk W, Chamberlain R, Rosenberg SA, Sutter G.

Adv Exp Med Biol. 1996;397:7-13. Review.

19.

In vitro propagation and production of hepatitis E virus from in vivo-infected primary macaque hepatocytes.

Tam AW, White R, Reed E, Short M, Zhang Y, Fuerst TR, Lanford RE.

Virology. 1996 Jan 1;215(1):1-9.

20.

Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells.

Ward GA, Stover CK, Moss B, Fuerst TR.

Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6773-7.

21.

Demonstration of in vitro infection of chimpanzee hepatocytes with hepatitis C virus using strand-specific RT/PCR.

Lanford RE, Sureau C, Jacob JR, White R, Fuerst TR.

Virology. 1994 Aug 1;202(2):606-14.

PMID:
8030225
22.

Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro.

Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, Murphy AN, Bird RE, Hoythya M, Fuerst TR, French DL, et al.

J Cell Physiol. 1993 Aug;156(2):235-46.

PMID:
8344982
23.

Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys.

Yasutomi Y, Koenig S, Haun SS, Stover CK, Jackson RK, Conard P, Conley AJ, Emini EA, Fuerst TR, Letvin NL.

J Immunol. 1993 Apr 1;150(7):3101-7.

PMID:
8454878
24.

Expression of human recombinant 72 kDa gelatinase and tissue inhibitor of metalloproteinase-2 (TIMP-2): characterization of complex and free enzyme.

Fridman R, Bird RE, Hoyhtya M, Oelkuct M, Komarek D, Liang CM, Berman ML, Liotta LA, Stetler-Stevenson WG, Fuerst TR.

Biochem J. 1993 Jan 15;289 ( Pt 2):411-6.

25.

Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions.

Fridman R, Fuerst TR, Bird RE, Hoyhtya M, Oelkuct M, Kraus S, Komarek D, Liotta LA, Berman ML, Stetler-Stevenson WG.

J Biol Chem. 1992 Aug 5;267(22):15398-405.

26.

Development and analysis of recombinant BCG vector systems.

Fuerst TR, de la Cruz VF, Bansal GP, Stover CK.

AIDS Res Hum Retroviruses. 1992 Aug;8(8):1451-5. No abstract available.

PMID:
1466980
28.

Use of recombinant BCG as a vaccine delivery vehicle.

Stover CK, de la Cruz VF, Bansal GP, Hanson MS, Fuerst TR, Jacobs WR Jr, Bloom BR.

Adv Exp Med Biol. 1992;327:175-82. Review. No abstract available.

PMID:
1295338
30.

New use of BCG for recombinant vaccines.

Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, Bansal GP, Young JF, Lee MH, Hatfull GF, et al.

Nature. 1991 Jun 6;351(6326):456-60.

PMID:
1904554
31.

Maturation of human immunodeficiency virus particles assembled from the gag precursor protein requires in situ processing by gag-pol protease.

Ross EK, Fuerst TR, Orenstein JM, O'Neill T, Martin MA, Venkatesan S.

AIDS Res Hum Retroviruses. 1991 May;7(5):475-83.

PMID:
1873082
32.

Molecular cloning and analysis of the chromosomal region 26A of Drosophila melanogaster.

Knipple DC, Fuerst TR, MacIntyre RJ.

Mol Gen Genet. 1991 Apr;226(1-2):241-9.

PMID:
1903503
33.

Development of BCG as a live recombinant vector system: potential use as an HIV vaccine.

Fuerst TR, Stover CK, de la Cruz VF.

Biotechnol Ther. 1991;2(1-2):159-78.

PMID:
1845119
34.

Product review. New mammalian expression vectors.

Moss B, Elroy-Stein O, Mizukami T, Alexander WA, Fuerst TR.

Nature. 1990 Nov 1;348(6296):91-2. No abstract available.

PMID:
2234068
35.

Mapping the fine specificity of a cytolytic T cell response to HIV-1 nef protein.

Koenig S, Fuerst TR, Wood LV, Woods RM, Suzich JA, Jones GM, de la Cruz VF, Davey RT Jr, Venkatesan S, Moss B, et al.

J Immunol. 1990 Jul 1;145(1):127-35.

PMID:
1694201
36.

Defining minimal requirements for antibody production to peptide antigens.

Goodman-Snitkoff G, Eisele LE, Heimer EP, Felix AM, Andersen TT, Fuerst TR, Mannino RJ.

Vaccine. 1990 Jun;8(3):257-62.

PMID:
1694612
38.
41.

Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein.

Chaudhary VK, Mizukami T, Fuerst TR, FitzGerald DJ, Moss B, Pastan I, Berger EA.

Nature. 1988 Sep 22;335(6188):369-72.

PMID:
2843774
43.

Roles of vaccinia virus in the development of new vaccines.

Moss B, Fuerst TR, Flexner C, Hugin A.

Vaccine. 1988 Apr;6(2):161-3. Review.

PMID:
3291453
45.
46.

Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.

Fuerst TR, Niles EG, Studier FW, Moss B.

Proc Natl Acad Sci U S A. 1986 Nov;83(21):8122-6.

Supplemental Content

Loading ...
Support Center